Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Minnicozzi

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
The Journal of Pharmacology and Experimental Therapeutics|June 18, 2002
Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitorM Motasim Billah, Nicola Cooper, Michael Minnicozzi, et al.
Bioorganic & Medicinal Chemistry Letters|August 9, 2007
Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitorsRongze Kuang, Ho-Jane Shue, David J Blythin, et al.
Bioorganic & Medicinal Chemistry Letters|June 1, 2002
8-Methoxyquinolines as PDE4 inhibitorsMotasim Billah, George M Buckley, Nicola Cooper, et al.
Bioorganic & Medicinal Chemistry Letters|June 1, 2002
Synthesis and profile of SCH351591, a novel PDE4 inhibitorMotasim Billah, Nicola Cooper, Francis Cuss, et al.
Journal of Leukocyte Biology|April 20, 2018
Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)Paneez Khoury, Praveen Akuthota, Steven J Ackerman, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
The Journal of Pharmacology and Experimental Therapeutics|June 18, 2002
Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitorM Motasim Billah, Nicola Cooper, Michael Minnicozzi, et al.
Bioorganic & Medicinal Chemistry Letters|August 9, 2007
Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitorsRongze Kuang, Ho-Jane Shue, David J Blythin, et al.
Bioorganic & Medicinal Chemistry Letters|June 1, 2002
8-Methoxyquinolines as PDE4 inhibitorsMotasim Billah, George M Buckley, Nicola Cooper, et al.
Bioorganic & Medicinal Chemistry Letters|June 1, 2002
Synthesis and profile of SCH351591, a novel PDE4 inhibitorMotasim Billah, Nicola Cooper, Francis Cuss, et al.
Journal of Leukocyte Biology|April 20, 2018
Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)Paneez Khoury, Praveen Akuthota, Steven J Ackerman, et al.
Pageof 2